DelMar Pharmaceuticals Inc (NASDAQ:DMPI)’s share price traded down 8.4% during trading on Wednesday . The company traded as low as $1.40 and last traded at $1.42. 1,019,279 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 1,631,491 shares. The stock had previously closed at $1.55.

Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th.

The stock has a market capitalization of $30.67, a price-to-earnings ratio of -2.09 and a beta of 1,227.20.

DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). equities analysts anticipate that DelMar Pharmaceuticals Inc will post -0.54 EPS for the current fiscal year.

In other DelMar Pharmaceuticals news, CEO Saiid Zarrabian acquired 60,900 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Several hedge funds have recently modified their holdings of DMPI. Franklin Resources Inc. purchased a new stake in shares of DelMar Pharmaceuticals in the second quarter worth $2,477,000. Sabby Management LLC purchased a new stake in shares of DelMar Pharmaceuticals in the second quarter worth $1,484,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of DelMar Pharmaceuticals in the third quarter worth $306,000. Institutional investors own 16.91% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “DelMar Pharmaceuticals (DMPI) Stock Price Down 8.4%” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.